The use of medication against attention deficit hyperactivity disorder in Denmark: a drug use study from a national perspective
The purpose of the study was to characterize the utilization of medication against attention deficit hyperactivity disorder (ADHD) in Denmark between 1995 and 2011 from a national perspective, by using population-based prescription data.
National data on drug use in Denmark between 1 January 1995 and 30 September 2011 were extracted from the Registry of Medicinal Product Statistics (RMPS). Drug utilization was characterized using descriptive statistics.
A total of 1,085,090 prescriptions issued to 54,020 persons were identified. The incidence rate was stable in the last 3 years of the study period, and a slightly decreasing incidence rate and a stabilizing prevalence were observed towards the end of this period. The therapeutic intensity was 6.7 defined daily dose/person/day, with large regional differences that ranged from 64 to 145 % of the national average. Methylphenidate accounted for 92.6 % of DDDs used. The general practitioner (GP) rarely initiated treatment, although treatment initiation based on the GP’s advice increased with older age of the patient. Maintenance treatment was found to be distributed roughly equally between prescriber types. For methylphenidate, 1 % of users accounted for 6.1 % of the drug volume and 50 % of users accounted for 84.4 %. The data therefore do not suggest a high proportion of heavy users.
The findings of this analysis are mostly reassuring, with the data indicating a seemingly stagnant incidence and prevalence rate and lacking evidence of heavy users. However, the prescriber profile for incident users and the large regional variances raise concerns. It is therefore vital that the use of ADHD drugs is closely monitored.
KeywordsADHD Drug utilization Denmark Psychostimulants Methylphenidate Atomoxetine
- 3.Danish National Board of Health. [Guide to medicamental treatment of children and adolescents with psychiatric disorders] [https://www retsinformation dk/Forms/R0710 aspx?id = 114817]; Last updated: 12-10-2010].
- 4.Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC (2011) et al. ADHD Drugs and Serious Cardiovascular Events in Children and Young Adults, N Engl J MedGoogle Scholar
- 5.Smith G, Jongeling B, Hartman P (2010) RUssell C, Landou L. Long-term outcomes associated with stimulation medication in the treatment of ADHD in children. Government of Western Australia; Published in, Raine ADHD StudyGoogle Scholar
- 6.Gillberg C, Melander H, von Knorring AL, Janols LO, Thernlund G, Hagglof B et al (1997) Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms. A randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 54(9):857–64PubMedCrossRefGoogle Scholar
- 16.Schubert I, Koster I, Lehmkuhl G (2010) The changing prevalence of attention-deficit/hyperactivity disorder and methylphenidate prescriptions: a study of data from a random sample of insurees of the AOK Health Insurance Company in the German State of Hesse, 2000–2007. Dtsch Arztebl Int 107(36):615–21PubMedGoogle Scholar
- 19.Pedersen E. [ADHD among adults - a life in frustration and chaos]. Månedsskrift for Almen Praksis 2008;May 86(5):537.Google Scholar